Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
TSHA Stock Chart & Stats
$4.61
-$0.08(-4.26%)
At close: 4:00 PM EST
$4.61
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$1.05 - $6.02
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.50M
Market Cap
$1.26B
Enterprise Value$730.39M
Total Cash (Recent Filing)$297.34M
Total Debt (Recent Filing)$69.08M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Mar 04, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding273,919,370
10 Day Avg. Volume2,433,756
30 Day Avg. Volume2,496,888
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.05
Price to Sales (P/S)51.93
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue115.75
Enterprise Value/Gross Profit121.25
Enterprise Value/Ebitda-7.40
Forecast
1Y Price Target
$12.17Price Target Upside163.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$4.11M
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestonesCompletion of dosing in the pivotal REVEAL Part B cohort and a six-month interim analysis could enable an earlier topline readout and a subsequent regulatory filing for the full Rett population if results are positive.
Label ExpansionFDA confirmation that limited pediatric safety data could support a broader label for TSHA-102 covering patients aged two and up if the pivotal study succeeds would expand the addressable patient population.
Regulatory Risk ReductionBreakthrough Therapy Designation combined with FDA alignment on competitive positioning reduces regulatory uncertainty and clarifies a differentiated approval pathway versus competing gene therapies.
Bears Say
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $1.05 and its highest was $6.02 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $1.26B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Mar 04, 2026 which is in 21 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.089 by -$0.001.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 273,919,370 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.089. Following the earnings report the stock price went down -4.26%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.17 (163.99% Upside)
$12.17 (163.99% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 565.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.42%
12-Months-Change
Fundamentals
Return on Equity
-64.93%
Trailing 12-Months
Asset Growth
75.65%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and regulatory progress with TSHA-102, including Breakthrough Therapy designation and strong clinical data, as well as strategic regaining of rights. However, this progress is tempered by increased expenses and net loss. Overall, the sentiment of the call leans positive due to the promising clinical results and regulatory advancements.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$12.17
▲(163.99% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
11.05% Insiders
9.76% Mutual Funds
49.37% Other Institutional Investors
17.61% Public Companies and Individual Investors